BoB@JPM: Ron Cooper, enGene

BoB@JPM: Ron Cooper, enGene

Author: Ben Comer January 26, 2026 Duration: 55:57

We love to hear from our listeners. Send us a message.

On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing early in CMC, and what to expect in 2026.  

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/



Navigating the complex journey from a promising scientific idea to a commercially viable therapy involves far more than lab work. Business Of Biotech, hosted by Ben Comer, exists in that crucial space where scientific ambition meets real-world execution. This podcast speaks directly to the founders, executives, and visionaries steering emerging biopharma companies, offering a grounded conversation about the non-scientific hurdles that define success. You'll hear detailed discussions on the organizational, financial, and operational realities of the industry-from securing funding and building a team to managing clinical trials, manufacturing, and regulatory pathways. Each episode leans on the hard-earned wisdom of accomplished guests who share commentary and practical best practices. The focus is consistently on the multifaceted challenges leaders face while trying to bring a company from its earliest stages to impact in the clinic and the market. For anyone involved in building a life sciences company, this podcast provides an essential, candid look at the entire ecosystem, making the daunting path of biotech entrepreneurship feel a bit more navigable and a lot less lonely.
Author: Language: English Episodes: 100

Business Of Biotech
Podcast Episodes
Biotech Story Time With Tal Zaks, M.D. (Part 2, Tall Tales with Tal) [not-audio_url] [/not-audio_url]

Duration: 54:04
We love to hear from our listeners. Send us a message. Dr. Tal Zaks is back, along with Advancing RNA's Anna Rose Welch, for part 2 of "Story Time With Tal." On this week's episode, we turn from his time navigating medic…
Risk Mitigation With Meira GTx's Zandy Forbes, Ph.D. [not-audio_url] [/not-audio_url]

Duration: 1:02:34
We love to hear from our listeners. Send us a message. Zandy Forbes, Ph.D. learned about business risk mitigation in the riskiest of business environments. She was a public markets healthcare investor on Wall Street for…
Biotech Story Time With Tal Zaks, M.D. (Part 1) [not-audio_url] [/not-audio_url]

Duration: 55:25
We love to hear from our listeners. Send us a message. Tal Zaks, M.D. was Chief Medical Officer at Moderna before, during, and immediately following the company's headline role during the COVID pandemic. If that doesn't…
A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D. [not-audio_url] [/not-audio_url]

Duration: 52:50
We love to hear from our listeners. Send us a message. This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the…
Novel Peptide Delivery With Revolo's Woody Bryan, Ph.D. [not-audio_url] [/not-audio_url]

Duration: 45:26
We love to hear from our listeners. Send us a message. Revolo Biotherapeutics President and CEO Woody Bryan, Ph.D. is pushing the boundaries of peptide therapeutic delivery. On this episode of the Business of Biotech, we…
Biopolitics With Allan Shaw [not-audio_url] [/not-audio_url]

Duration: 49:54
We love to hear from our listeners. Send us a message. The notion that political influence has no place in biology appears poised for a test it hasn’t studied for. Trump administration nominations, from RFK, Jr. to HHS a…
T-Cells For The Win With Adaptimmune's Adrian Rawcliffe [not-audio_url] [/not-audio_url]

Duration: 1:01:35
We love to hear from our listeners. Send us a message. In August of this year, the first TCR cell therapy to be approved for use in the U.S. was greenlighted by the FDA for patients with unresectable or metastatic synovi…
Serving The Underserved With Gates MRI's Claire Wagner, M.D. [not-audio_url] [/not-audio_url]

Duration: 46:48
We love to hear from our listeners. Send us a message. On this episode of the Business of Biotech, Bill and Melinda Gates Medical Research Institute's (Gates MRI) Dr. Claire Wagner joins us to share insights into her wor…